Compare JMIA & AMLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JMIA | AMLX |
|---|---|---|
| Founded | 2012 | 2014 |
| Country | Germany | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2019 | 2022 |
| Metric | JMIA | AMLX |
|---|---|---|
| Price | $9.30 | $14.10 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $16.75 | ★ $18.75 |
| AVG Volume (30 Days) | ★ 3.4M | 1.5M |
| Earning Date | 02-10-2026 | 03-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $188,930,000.00 | N/A |
| Revenue This Year | $29.81 | N/A |
| Revenue Next Year | $16.58 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 12.80 | N/A |
| 52 Week Low | $1.60 | $2.60 |
| 52 Week High | $14.72 | $17.49 |
| Indicator | JMIA | AMLX |
|---|---|---|
| Relative Strength Index (RSI) | 32.73 | 50.20 |
| Support Level | $10.44 | $12.94 |
| Resistance Level | $12.37 | $15.11 |
| Average True Range (ATR) | 0.81 | 0.92 |
| MACD | -0.37 | -0.11 |
| Stochastic Oscillator | 3.78 | 41.40 |
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. It has one operating segment which is the business of researching and developing therapeutics for neurodegenerative disorder and endocrine conditions.